Abstract: Objective To investigate the effects of Gankang Ⅱ on the hepatitis endotoxemia and explore its mechanism of action, provide the basis for clinical use. Methods Total of 40 patients with severe hepatitis were divided into treatment group (20 cases) and control group (20 cases). The basis of the control group received liver protective, jaundice-relidf and other comprehensive treatment, the treatment group received conventional liver protectve in severe hepatitis, jaundice-relief and other comprehensive treatment, the addition of Gankang No.Ⅱ day one, bid, for 2 weeks. Both groups before and after treatment were detected in serum of patients TBil, ALB, prothrombin activity (PTA), serum endotoxin (endotoxin, ET), tumor necrosis factor α (TNF-α) levels. Results The TNF-α, ET, ALT, TBil levels decreased significantly after treatment (all P ＜ 0.01), ALB, PTA levels were significantly increased (both P ＜ 0.05), in treatment group than the control group. In two groups, TNF-α, ET, TBil, ALB, PTA level difference were statistically significant (all P ＜ 0.01). The control and treatment groups improved rates were 40% and 60%, respectively, the two groups showed no statistically significant (P ＞ 0.05). Conclusions Gankang Ⅱ can significantly improve liver function, serum endotoxin levels, improve the treatment of severe hepatitis. Its therapeutic mechanism may be related to the inhibition of the production and release of toxins and the promotion of related toxins.